Cancer Antigen 125 (CA125), a surface antigen, is associated with epithelial-ovarian cancer. CA125, a high molecular-weight glycoprotein, is found in serum. Studies have shown that high serum CA125 levels are possible in individuals. In 60% of women, the serum CA125 concentration exceeds 35 units per milliliter.
Patients with disseminated or ovarian carcinoma are more likely to have ovarian cancer than patients with regular ovarian cancer. Uterine fibroids and acute salpingitis are all possible. Hepatic diseases, liver disease, and inflammation of the peritoneum are also possible. A high-quality CA 125 test kit specificity can be increased by examination.
It may be possible to use serum CA125 concentration. Monitoring treatment and discerning between good and poor response to treatment Progressive malignant disease that is resistant to treatment. CA125 has been the most widely used chemotherapy. It is the most sensitive marker for residual epithelial cancer of the ovary.
CA125 ELISA Test is based upon the principle of a solid-phase enzyme-linked immunosorbent assay. Monoclonal antibodies are used in the assay. It is used to test against an antigenic determinant specific to the CA125 intact molecule. Anti-CA125 rabbit antibody conjugated to horseradish oxidase (HRP), is in the antibody enzyme conjugate.
The two antibodies can react simultaneously in the test sample. This has led to the CA125 molecules sandwiched between the enzyme-linked and solid phases antibodies. After 90 minutes at 37°C, incubation, the wells should be rinsed with water. To remove unbound-labeled antibodies TMB Reagent solution is also added.